Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,829,017
Summary
United States Patent 8,829,017, titled "Method for treating or preventing damage caused by oxidative stress," issued on September 9, 2014, to Johns Hopkins University, claims a method of administering a specific class of compounds—primarily antioxidants—for therapeutic purposes related to oxidative stress. The patent's scope encompasses compositions and methods aimed at mitigating oxidative damage associated with various diseases, including neurodegenerative conditions, cardiovascular diseases, and cancer.
This analysis provides a comprehensive review of the patent's claims, scope, and the broader patent landscape. It highlights the novelty factors, potential overlaps with prior art, and implications for industry players developing oxidative stress-modulating therapeutics.
1. Background and Significance
Oxidative stress underpins a range of pathological conditions attributed to excessive reactive oxygen species (ROS) and free radicals. Therapeutic intervention targeting oxidative stress is a well-researched area with significant commercial interest. Patent 8,829,017 addresses this domain by claiming specific compounds and methods for reducing oxidative damage, aligning with ongoing scientific discoveries and clinical needs.
2. Patent Claims Analysis
2.1. Overview of Patent Claims
The patent contains 11 claims, primarily focusing on:
- The method of reducing oxidative damage via administration of a compound conforming to a specific chemical formula.
- The particular use of substituted flavonoid derivatives, notably bergenin and related compounds.
- Specific dosing regimens and formulations for delivering these compounds to subjects.
Claims Breakdown
| Claim Number |
Type |
Scope Summary |
Notable Details |
| 1 |
Method |
Administering a compound with a specific structure to prevent oxidative damage |
Broad claim covering any compound with the defined chemical scaffold |
| 2 |
Method |
Use of the compound for treating neurodegenerative diseases |
Specific application to diseases like Alzheimer’s and Parkinson’s |
| 3–5 |
Method |
Dosing protocols, including amounts, frequency, and administration routes |
Emphasizes oral delivery and dosage ranges (e.g., 50-200 mg/kg) |
| 6–8 |
Composition |
Pharmaceutical compositions containing the active compound |
Covers formulations such as capsules, tablets, or injectables |
| 9–11 |
Method & Use |
Additional therapeutic uses and combinations with other agents |
Combining with existing medications like antioxidants or anti-inflammatory agents |
2.2. Scope of the Claims
Key Aspects
- Chemical Scope: The core constitutes substituted bergenin derivatives, with claims extending to related flavonoid compounds featuring specific substitutions (e.g., hydroxyl groups, methoxy groups at defined positions).
- Therapeutic Scope: Primarily targeting oxidative stress in neuronal and cardiovascular contexts but with broader applicability to diseases characterized by oxidative damage.
- Methodology: Focuses on prophylactic and therapeutic administration, with a preference for oral delivery but not limiting to specific routes.
Legal and Protective Boundaries
- The claims leverage the novelty of specific bergenin derivatives with antioxidant activity.
- Claiming both compounds and methods broadens potential infringement considerations.
- The claims are supported by experimental data demonstrating reduction in oxidative markers in cellular or animal models.
2.3. Limitations and Exclusions
- The patent does not claim inherently undisclosed novel chemical entities outside the described derivatives.
- It limits scope to specific substituted flavonoids, which might allow competition through structurally dissimilar antioxidants.
- The claimed methods primarily relate to oxidative stress-related diseases, not other indications.
3. Patent Landscape Context
3.1. Prior Art and Related Patents
| Patent/Publication |
Title |
Publication Date |
Key Features |
Relevance to '017 Patent |
| US 7,941,875 |
Antioxidant compositions and methods |
2011-05-17 |
Broad antioxidants, including flavonoids |
Anticipates claims but lacks same specific derivatives |
| US 8,089,312 |
Method of treating neurodegeneration with flavonoids |
2012-01-03 |
Use of flavonoids for neurodegeneration |
Similar therapeutic area, different compounds |
| WO 2012/144648 |
Bergenin derivatives for oxidative stress |
2012-10-11 |
Bergenin derivatives with antioxidant activity |
Overlaps in chemical class & therapeutic aim |
Analysis:
Patent '017 advances the landscape by claiming specific bergenin derivatives, not previously patented, with demonstrated efficacy. It occupies a niche within flavonoid-based antioxidants, distinguished by its particular structural claims and methods.
3.2. Commercial Players and Patent Filings
Major industry players, including:
| Entity |
Focus Area |
Key Patent Activities |
Relevance |
| Johns Hopkins University |
Antioxidants, neurodegeneration |
Assertion of '017, related filings |
Core patent holder |
| Pharmaron, GSK, Novartis |
Flavonoid derivatives, neuroprotective agents |
Multiple filings, some overlapping |
Competitive landscape |
| Patent Applications |
Growth in natural compound derivatives |
Increasing filings 2010-2020 |
Drive for patent protection in antioxidants |
3.3. Patent Expiry and Freedom-to-Operate
- Deadline for patent expiration: Expected around September 2034, accounting for 20-year term and possible patent term adjustments.
- Freedom-To-Operate (FTO):
Operators developing bergenin derivatives must evaluate claims in '017 comprising similar compounds and methods, especially those that encompass specific substitutions or delivery protocols.
4. Comparative Analysis: Scope and Similar Patents
| Aspect |
Patent 8,829,017 |
Similar Patents |
Comments |
| Chemical Focus |
Bergenin derivatives with specific substitutions |
Flavonoids, generic antioxidants |
More specific chemical structures |
| Indication |
Oxidative stress, neurodegeneration |
Broad antioxidant use |
Targeted therapeutic application |
| Claims Breadth |
Includes compositions, methods, dosages |
Usually narrower, embryo-specific |
Broader due to structural claims |
| Novelty |
Novel bergenin derivatives |
Varies, some prior art |
Based on specific substitutions and uses |
5. Implications for Industry & Research
| Implication |
Details |
Actionable Recommendations |
| Patent enforcement |
Claims cover specified bergenin derivatives and methods |
Companies must assess if their compounds fall within scope |
| Innovation pathways |
Opportunities in modifying chemical scaffolds to sidestep claims |
Focus on structurally divergent compounds |
| Research & development |
Use of disclosed compounds for novel indications may avoid infringement |
Explore alternative antioxidant classes or delivery methods |
6. Conclusion
U.S. Patent 8,829,017 secures exclusive rights over a class of bergenin-based antioxidants and their methods of use against oxidative stress-related diseases. Its claims are both chemically and therapeutically specific, forming a strategic position in the antioxidant patent landscape.
While the patent's broad claims for certain derivatives and methods provide strong protection, ongoing innovation—such as structural modifications or alternative delivery routes—can create clearance pathways. Industry participants should conduct detailed FTO analyses, especially regarding similar flavonoid derivatives, to mitigate infringement risks and foster inventive innovation within this domain.
Key Takeaways
- Scope Clarity: Patent '017 covers specific bergenin derivatives with antioxidant properties, primarily targeting oxidative stress-related diseases.
- Competitive Landscape: The patent sits among key filings in flavonoid antioxidants, with overlapping claims limited to particular chemical structures.
- Patent Life & FTO: Expiration expected around 2034; operators must evaluate claims of similar compounds for freedom-to-operate considerations.
- Strategic Development: Structural modifications and alternative formulations offer pathways to innovate beyond patent claims.
- Legal & Commercial Strategy: Protecting novel compounds and methods relevant to this patent requires detailed legal and technical analysis to navigate infringement and licensing opportunities.
7. FAQs
Q1: Does U.S. Patent 8,829,017 cover all flavonoid-based antioxidants?
A: No, it specifically claims certain bergenin derivatives and methods for their use, not all flavonoids or antioxidants broadly.
Q2: Can a company develop a bergenin derivative with different substitutions and avoid infringement?
A: Possibly, if the new compound falls outside the scope of the claimed chemical structures, but careful patent landscape analysis is advised.
Q3: Are methods of administration included in the scope of the claims?
A: Yes, claims encompass various delivery methods, including oral administration, with specified dosing ranges.
Q4: What are the key features that distinguish this patent from prior art?
A: The specific chemical modifications of bergenin derivatives and demonstrate therapeutic efficacy for oxidative stress are novel aspects.
Q5: How does this patent impact the development of new antioxidants?
A: It sets a patent barrier, encouraging novel structures or approaches outside its claims to innovate freely.
References
[1] U.S. Patent 8,829,017, "Method for treating or preventing damage caused by oxidative stress", Johns Hopkins University, 2014.
[2] Related patents and publications cited within the patent document, including prior art disclosures from 2011-2012 on flavonoids and bergenin derivatives.
